Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Diabetes, Obesity & Metabolism|May 8, 2018
Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017Helen J Curtis, John M Dennis, Beverley M Shields, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2009
Phosphodiesterase 8B gene polymorphism is associated with subclinical hypothyroidism in pregnancyBeverley M Shields, Rachel M Freathy, Bridget A Knight, et al.
Diabetologia|November 21, 2022
The impact of population-level HbA<sub>1c</sub> screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysisKatherine G Young, Andrew P McGovern, Inês Barroso, et al.
Diabetes Care|January 11, 2008
Mutations in the glucokinase gene of the fetus result in reduced placental weightBeverley M Shields, Gill Spyer, Annabelle S Slingerland, et al.
Diabetes, Obesity & Metabolism|January 6, 2025
Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort studyRhian Hopkins, Katherine G Young, Nicholas J Thomas, et al.
BMJ Open|December 20, 2013
Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational studyRichard A Oram, Andrew Rawlingson, Beverley M Shields, et al.
Diabetes Care|December 19, 2014
Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretorsRichard A Oram, Timothy J McDonald, Beverley M Shields, et al.
Diabetologia|October 7, 2017
Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemiaSuzy V Hope, Bridget A Knight, Beverley M Shields, et al.
Plos One|August 4, 2012
EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperatureTimothy J McDonald, Mandy H Perry, Roy W A Peake, et al.
Nature Medicine|December 8, 2022
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster studyBeverley M Shields, Catherine D Angwin, Maggie H Shepherd, et al.
Pageof 12